Find the next decision worth funding

Explore Opportunities

Most actionable first. Assess the next decision, not the size of the database.

877 matching trial–asset observations. These are not unique or cleared acquisitions. 0 have all four gates supported in this view; entered assessments still require review.

How “most actionable” works

Explicit ordinal order: all four gates PASS → concerns needing review → unresolved leads → fatal failures. Names and IDs break ties. UNKNOWN never counts as a pass. This is not an efficacy score or valuation. Private assumptions affect only your own results.

WATCH · TERMINATED

Mavacamten

Cardiomyopathy, Hypertrophic

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT Trial terminated because of lack of efficacy in the short term acute phase

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

Trial terminated because of lack of efficacy in the short term acute phase

Why stranded: Endpoint failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-18. Registry source

WATCH · TERMINATED

MBX-102

Type 2 Diabetes Mellitus

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT MBX-102 did not meet the target efficacy profile of HbA1c change.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

MBX-102 did not meet the target efficacy profile of HbA1c change.

Why stranded: Endpoint failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-18. Registry source

WATCH · TERMINATED

MEDI-507

Lymphoproliferative Disorders

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-06-14. Registry source

WATCH · TERMINATED

MEDI-507

Lymphoma, Leukemia, Cancer

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

After review of safety events and have decided that further dose escalation of MEDI-507 as a single agent is not feasible.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-06-14. Registry source

WATCH · SUSPENDED

Melan-A analog peptide

Melanoma

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2005-09-12. Registry source

WATCH · TERMINATED

melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d

Trypanosomiasis, African

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2006-05-26. Registry source

WATCH · TERMINATED

melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d

Trypanosomiasis, African

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2006-05-26. Registry source

WATCH · TERMINATED

melatonin 0.5 mg

Hot Flashes

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2006-02-07. Registry source

WATCH · TERMINATED

Metformin

Type 2 Diabetes Mellitus

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT MBX-102 did not meet the target efficacy profile of HbA1c change.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

MBX-102 did not meet the target efficacy profile of HbA1c change.

Why stranded: Endpoint failure · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-18. Registry source

WATCH · TERMINATED

Metformin

Coronary and Peripheral Endothelial Dysfunction

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT UNKNOWN

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

UNKNOWN

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-10-05. Registry source

WATCH · WITHDRAWN

Metformin

Healthy

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT The sponsor made a business decision to withdraw the trial.

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

The sponsor made a business decision to withdraw the trial.

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2026-09-08. Registry source

WATCH · TERMINATED

Methachoine

Asthma, Recurrent Cough

Human SignalUNKNOWN

Cheap TruthUNKNOWN

AcquirabilityUNKNOWN

SOURCE FACT the study has recently ended, all information gathred as planed

Rescueability · inferenceUNKNOWN

Current controlUNKNOWN

Next truth · USD / monthsUNKNOWN / UNKNOWN

Restart · inferenceUNKNOWN

Why this survived: Source-backed stopping context warrants a review, not qualification.

Next Best Diligence Question: Resolve scoped human outcomes and current transferable rights before capital.

Principal risk: Transferable rights and decision-quality human evidence remain unresolved.

Investigate opportunity

Source, stopping context and uncertainty

the study has recently ended, all information gathred as planed

Why stranded: Unknown · MODEL INFERENCE. Why now: UNKNOWN — no sourced catalyst established

Acquisition range: UNKNOWN · Market Pull: UNKNOWN

Confidence UNKNOWN. Source update 2007-10-30. Registry source